Reported Sunday, Johnson & Johnson Says Impella Outcomes Depend On Patient Selection, Timing And Post-Procedural Care, Citing Lower Mortality In Three TCT Analyses Versus CHIP-BCIS3; PROTECT IV Results Expected 2027
Reported Sunday, Johnson & Johnson Says Impella Outcomes Depend On Patient Selection, Timing And Post-Procedural Care, Citing Lower Mortality In Three TCT Analyses Versus CHIP-BCIS3; PROTECT IV Results Expected 2027
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed